The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

32 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
21
Development of new Malt1 inhibitors and probes.EBI
Leiden University
6
MALT1 Inhibitors May Potentially Treat Lymphomas and Autoimmune Disorders.EBI
Therachem Research Medilab (India)
27
Identification ofß-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.EBI
Institute of Basic Science (Ibs)
26
MALT1 Inhibitors and Degraders: Strategies for NF-κB-Driven Malignancies.EBI
China Pharmaceutical University
6
MALT1 Inhibitors for Treating Cancer and Immunological Diseases.EBI
Smith, Gambrell & Russell
12
The Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT-1) Protease as Potential Treatment of ABC-DLBCL and Similar Diseases.EBI
PI Health Sciences
37
Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one" Scaffold for the Treatment of B Cell Lymphoma.EBI
Shanghai Institute of Materia Medica
42
Discovery of orally bioavailable inhibitors of MALT1 with in vivo activity for psoriasis.EBI
Toray Industries
33
Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.EBI
AstraZeneca
75
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.EBI
Chinese Academy of Sciences
42
Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.EBI
Toray Industries
12
Optimization of the EBI
Novartis Pharma
27
Discovery of Potent, Highly Selective, and EBI
Novartis Institutes For Biomedical Research
28
Quinoline and thiazolopyridine allosteric inhibitors of MALT1.EBI
Harvard Medical School
3
Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities.EBI
National Cancer Institute
43
Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.EBI
Janssen Research & Development
3
Use of Non-Natural Amino Acids for the Design and Synthesis of a Selective, Cell-Permeable MALT1 Activity-Based Probe.EBI
Ku Leuven
7
Peptide-based covalent inhibitors of MALT1 paracaspase.EBI
Harvard Medical School
21
N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.EBI
Novartis Institutes For Biomedical Research
15
Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1)BDB
Pontificia Universidad Catolica De Chile
4
DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH N ALPHA-AROYL-N-ARYL-PHENYLALANINAMIDESBDB
The State University of New Jersey
13
HETEROCYCLE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODSBDB
Pretzel Therapeutics
1022
Substituted pyrazolo[5′,1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitorsBDB
Takeda Pharmaceutical
14
N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENTBDB
University of Zurich
18
MODULATORS OF PROGRAMMED DEATH-LIGAND-1BDB
Southern Research Institute
119
Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferaseBDB
A*Star
2
ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERSBDB
University of Mississippi
449
Heteroaryl compounds and their use as therapeutic drugsBDB
Dong-A Socio Holdings
825
Pyridazinones as PARP7 inhibitorsBDB
Ribon Therapeutics
14
Small-molecule HSP90 inhibitorsBDB
Sloan-Kettering Institute For Cancer Research
9
 
Inhibition of SARS-CoV-2 main protease by allosteric drug-bindingBDB
Center For Free-Electron Laser Science
37
1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitorsBDB
Infex Therapeutics